

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL02): an international, multicentre, open-label, phase 2 trial

Lancet Oncology, The

18, 75-87

DOI: [10.1016/s1470-2045\(16\)30559-9](https://doi.org/10.1016/s1470-2045(16)30559-9)

Citation Report

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. <i>Drugs</i> , 2017, 77, 113-130.  | 4.9 | 44        |
| 2  | Comprehensive genomic profiling of malignant phyllodes tumors of the breast. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 597-602.   | 1.1 | 38        |
| 3  | A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2017, 116, 884-892.   | 2.9 | 69        |
| 4  | Rucaparib: First Global Approval. <i>Drugs</i> , 2017, 77, 585-592.  | 4.9 | 61        |
| 5  | Immunotherapy and epithelial ovarian cancer: a double-edged sword?. <i>Annals of Oncology</i> , 2017, 28, 909-910.   | 0.6 | 4         |
| 6  | PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 153-165. | 2.0 | 37        |
| 7  | Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. <i>Nature Genetics</i> , 2017, 49, 856-865.   | 9.4 | 220       |
| 8  | PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 253-267.  | 1.4 | 78        |
| 9  | Emerging therapies for breast cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 98.  | 6.9 | 60        |
| 10 | The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 687-696.  | 1.0 | 9         |
| 11 | Use of precision methods to accelerate drug development in oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 109-120.   | 0.4 | 0         |
| 12 | The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. <i>Current Treatment Options in Oncology</i> , 2017, 18, 27.   | 1.3 | 25        |
| 13 | Ovarian cancer stem cells more questions than answers. <i>Seminars in Cancer Biology</i> , 2017, 44, 67-71.  | 4.3 | 128       |
| 14 | Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. <i>International Journal of Clinical Oncology</i> , 2017, 22, 611-618.  | 1.0 | 10        |
| 15 | Targeting ATR in cancer medicine. <i>Current Problems in Cancer</i> , 2017, 41, 302-315.   | 1.0 | 43        |
| 16 | Oesophageal cancer. <i>Lancet, The</i> , 2017, 390, 2383-2396.   | 6.3 | 796       |
| 17 | PARP Inhibitors in Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 37.   | 1.3 | 50        |
| 18 | Secondary Somatic Mutations Restoring <i>hRAD51C</i> and <i>hRAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998.                           | 7.7 | 310       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Unravelling the biology of SCLC: implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 549-561.  | 12.5 | 336       |
| 20 | Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. <i>Gynecologic Oncology</i> , 2017, 146, 217-224.  | 0.6  | 89        |
| 21 | The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. <i>Cancer</i> , 2017, 123, 1912-1924.  | 2.0  | 52        |
| 22 | Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. <i>Clinical Cancer Research</i> , 2017, 23, 1638-1646.  | 3.2  | 136       |
| 23 | Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?. <i>Annals of Oncology</i> , 2017, 28, 920-921.   | 0.6  | 1         |
| 24 | A Phase II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4095-4106.  | 3.2  | 213       |
| 25 | Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. <i>British Journal of Cancer</i> , 2017, 116, 1294-1301.  | 2.9  | 13        |
| 26 | Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. <i>European Journal of Cancer</i> , 2017, 76, 52-59.   | 1.3  | 10        |
| 27 | Niraparib for the treatment of ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 631-640.   | 0.9  | 35        |
| 28 | PARP inhibitors: Synthetic lethality in the clinic. <i>Science</i> , 2017, 355, 1152-1158.   | 6.0  | 1,826     |
| 29 | Targeted Therapies for Ovarian Cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 139-152.   | 1.4  | 95        |
| 30 | PARP inhibition—moving beyond BRCA-mutated disease. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 71-71.   | 12.5 | 2         |
| 31 | Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 509-513.   | 0.6  | 32        |
| 32 | Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. <i>Clinical Oncology</i> , 2017, 29, 778-786.   | 0.6  | 13        |
| 33 | Optimizing treatment in recurrent epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1147-1158.   | 1.1  | 107       |
| 34 | Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. <i>Cancer Science</i> , 2017, 108, 2213-2220.  | 1.7  | 22        |
| 35 | Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients. <i>Drugs and Aging</i> , 2017, 34, 821-831.   | 1.3  | 4         |
| 36 | Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1637-1651. | 5.1  | 233       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 39 | The <i>HRD</i> Decision“</i>Which PARP Inhibitor to Use for Whom and When. <i>Clinical Cancer Research</i> , 2017, 23, 7155-7157.  | 3.2  | 22        |
| 40 | Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. <i>European Journal of Cancer</i> , 2017, 86, 5-14.  | 1.3  | 49        |
| 41 | PARP inhibitors: Clinical utility and possibilities of overcoming resistance. <i>Gynecologic Oncology</i> , 2017, 147, 695-704.  | 0.6  | 172       |
| 42 | Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1007, 1-16.  | 0.8  | 3         |
| 43 | FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. <i>Gynecologic Oncology</i> , 2017, 147, 3-10.  | 0.6  | 36        |
| 44 | Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions. <i>Cancer Discovery</i> , 2017, 7, 937-939.   | 7.7  | 33        |
| 45 | Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017, 147, 267-275. | 0.6  | 222       |
| 46 | Germline genetic variants with implications for disease risk and therapeutic outcomes. <i>Physiological Genomics</i> , 2017, 49, 567-581.  | 1.0  | 8         |
| 47 | PARP inhibitors for targeted treatment in ovarian cancer. <i>Lancet, The</i> , 2017, 390, 1929-1930.   | 6.3  | 30        |
| 48 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 1949-1961.   | 6.3  | 1,261     |
| 49 | Garcinone E induces apoptosis and inhibits migration and invasion in ovarian cancer cells. <i>Scientific Reports</i> , 2017, 7, 10718.   | 1.6  | 34        |
| 50 | Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors. <i>Current Obstetrics and Gynecology Reports</i> , 2017, 6, 207-218.  | 0.3  | 1         |
| 51 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1274-1284.      | 5.1  | 1,376     |
| 52 | FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation“Associated Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7165-7170.   | 3.2  | 133       |
| 53 | Oesophageal cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17048.  | 18.1 | 671       |
| 54 | Veliparib Monotherapy to Patients With <i>BRCA</i> Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1842-1849.     | 1.2  | 33        |
| 55 | <i>BRCA</i> mutation in ovarian cancer: testing, implications and treatment considerations. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 519-531.  | 1.4  | 96        |
| 56 | Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6400-6410.   | 3.2  | 59        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 59 | CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. <i>Scientific Reports</i> , 2017, 7, 16827.  | 1.6 | 68        |
| 60 | Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer. <i>Trends in Molecular Medicine</i> , 2017, 23, 1121-1137.  | 3.5 | 48        |
| 61 | Optimism and the continued promise of maintenance chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 879-880.   | 1.1 | 2         |
| 62 | Missing a GOLDen opportunity in gastric cancer. <i>Lancet Oncology</i> , The, 2017, 18, 1561-1563.   | 5.1 | 11        |
| 64 | Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1583-1591.  | 1.4 | 23        |
| 65 | Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. <i>Cancer Letters</i> , 2017, 405, 38-45.   | 3.2 | 80        |
| 66 | Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 4.   | 3.6 | 106       |
| 67 | Germline Testing for Predisposition to Ovarian/Breast Cancer Should be Routinely Recommended in all Patients with Invasive Epithelial Ovarian Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 27-30.                     | 0.1 | 0         |
| 68 | Treatment of recurrent ovarian cancer. <i>Annals of Oncology</i> , 2017, 28, viii51-viii56.  | 0.6 | 200       |
| 69 | Whence High-Grade Serous Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 443-448.   | 1.8 | 15        |
| 70 | Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 358-369. | 1.8 | 9         |
| 71 | Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3029-3037.   | 1.0 | 49        |
| 72 | Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2171.  | 1.8 | 83        |
| 73 | Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. <i>Cancers</i> , 2017, 9, 109.   | 1.7 | 36        |
| 75 | Current status of poly(ADP-ribose) polymerase inhibitors and future directions. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5195-5208.   | 1.0 | 96        |
| 76 | Role and clinical application of next-generation sequencing (NGS) for ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e51.  | 1.0 | 3         |
| 77 | Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2539-2551.                                | 1.0 | 45        |
| 78 | <div>Emerging treatment options for ovarian cancer: focus on rucaparib</div>. <i>International Journal of Women's Health</i> , 2017, Volume 9, 913-924.  | 1.1 | 19        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 79 | The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. <i>Oncology Research</i> , 2017, 25, 1441-1451.   | 0.6 | 3         |
| 80 | Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 13.  | 3.6 | 26        |
| 81 | PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 18.   | 3.6 | 42        |
| 82 | Germline Testing for Predisposition to Breast/Ovarian Cancer Should Only be Offered to Selected Patients with Epithelial Ovarian Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 31-36.  | 0.1 | 0         |
| 83 | Olaparib and somatic BRCA mutations. <i>Oncotarget</i> , 2017, 8, 43598-43599.   | 0.8 | 11        |
| 84 | Drug Monographs: Olaratumab and Rucaparib. <i>Hospital Pharmacy</i> , 2017, 52, 258-263.   | 0.4 | 2         |
| 85 | Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases <i>in vitro</i> toxicity of PARP inhibition by preventing Rad51 foci formation in <i>BRCA</i> wild type high-grade serous ovarian cancer. <i>Oncotarget</i> , 2017, 8, 111026-111040.  | 0.8 | 64        |
| 86 | Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?. <i>Journal of Clinical Oncology</i> , 2017, 35, 3999-4002.  | 0.8 | 14        |
| 87 | Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1151-1153.  | 0.8 | 2         |
| 88 | Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2193-2202. | 0.8 | 209       |
| 89 | The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others. <i>Biomedicine and Pharmacotherapy</i> , 2018, 99, 552-560.  | 2.5 | 32        |
| 90 | The effect of lncRNA HOTAIR on chemoresistance of ovarian cancer through regulation of <i>HOXA7</i> . <i>Biological Chemistry</i> , 2018, 399, 485-497.  | 1.2 | 28        |
| 92 | PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 647-658.   | 1.1 | 58        |
| 93 | Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 18.  | 0.4 | 6         |
| 94 | Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions. <i>Clinical Therapeutics</i> , 2018, 40, 361-371.   | 1.1 | 41        |
| 95 | Rucaparib: a new treatment option for ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 765-771.  | 0.9 | 7         |
| 96 | A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. <i>Cell Reports</i> , 2018, 23, 918-929.  | 2.9 | 39        |
| 97 | Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. <i>Cell Reports</i> , 2018, 23, 100-111.   | 2.9 | 60        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 98  | Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. <i>Cell Reports</i> , 2018, 23, 213-226.e3.  | 2.9  | 83        |
| 99  | Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?. <i>Leukemia</i> , 2018, 32, 1561-1566.  | 3.3  | 39        |
| 100 | Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 207-215.     | 5.1  | 167       |
| 101 | Management of the toxicities of common targeted therapeutics for gynecologic cancers. <i>Gynecologic Oncology</i> , 2018, 148, 591-600.  | 0.6  | 23        |
| 103 | Rucaparib for the treatment of ovarian cancer. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 151-161.   | 0.5  | 0         |
| 104 | Targeting DNA repair: the genome as a potential biomarker. <i>Journal of Pathology</i> , 2018, 244, 586-597.   | 2.1  | 41        |
| 105 | Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). <i>Pathology</i> , 2018, 50, 222-237.  | 0.3  | 23        |
| 106 | Advances in ovarian cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 17-38.   | 1.1  | 393       |
| 107 | BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. <i>Clinical Breast Cancer</i> , 2018, 18, 184-188. | 1.1  | 34        |
| 108 | The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 161-175.   | 1.1  | 16        |
| 109 | Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. <i>Chemical Reviews</i> , 2018, 118, 1599-1663.   | 23.0 | 64        |
| 110 | Proteomic Analysis of the Downstream Signaling Network of PARP1. <i>Biochemistry</i> , 2018, 57, 429-440.  | 1.2  | 31        |
| 111 | Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 359-367.   | 1.4  | 5         |
| 112 | Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. <i>Women's Health</i> , 2018, 14, 174550571775069.  | 0.7  | 7         |
| 113 | Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma. <i>Journal of Molecular Medicine</i> , 2018, 96, 527-536.             | 1.7  | 18        |
| 114 | Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <i>Nature Medicine</i> , 2018, 24, 628-637.  | 15.2 | 649       |
| 115 | Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 7-14.   | 3.4  | 51        |
| 116 | Disparities in genetics assessment for women with ovarian cancer: Can we do better?. <i>Gynecologic Oncology</i> , 2018, 149, 84-88.   | 0.6  | 50        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 117 | Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 903-914.                              | 1.2 | 27        |
| 118 | PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Oncology Research and Treatment</i> , 2018, 41, 226-234.  | 0.8 | 10        |
| 121 | The Current Landscape of PARP Inhibitors in Ovarian Cancer. <i>Current Obstetrics and Gynecology Reports</i> , 2018, 7, 20-27.  | 0.3 | 2         |
| 122 | BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. <i>Cancer Cell</i> , 2018, 33, 401-416.e8.   | 7.7 | 215       |
| 123 | A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 938-946.   | 2.9 | 29        |
| 124 | Emerging growth factor receptor antagonists for ovarian cancer treatment. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 1-16.   | 1.0 | 2         |
| 125 | Neurological complications of new chemotherapy agents. <i>Neuro-Oncology</i> , 2018, 20, 24-36.   | 0.6 | 28        |
| 126 | Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 326-333.  | 3.2 | 40        |
| 127 | Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 209-216.   | 3.2 | 47        |
| 129 | Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2018, 20, 274-285. | 1.2 | 5         |
| 130 | Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2. <i>Advances in Anatomic Pathology</i> , 2018, 25, 85-95.  | 2.4 | 24        |
| 131 | Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018, 148, 281-285.   | 0.6 | 52        |
| 132 | PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. <i>Oncogene</i> , 2018, 37, 341-351.  | 2.6 | 98        |
| 133 | Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. <i>Clinical Cancer Research</i> , 2018, 24, 777-783.   | 3.2 | 171       |
| 134 | Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. <i>Gynecologic Oncology</i> , 2018, 148, 79-85.   | 0.6 | 29        |
| 135 | Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.   | 1.5 | 215       |
| 136 | Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.  | 1.5 | 129       |
| 137 | SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.   | 1.5 | 19        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 138 | Sustained Exceptional Response to Poly (ADP-Ribose) Polymerase Inhibition Plus Temozolomide in Metastatic Melanoma With DNA Repair Deficiency. <i>JCO Precision Oncology</i> , 2018, 2, 1-7.                                    | 1.5 | 0         |
| 139 | Moving From Mutation to Actionability. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 495-503.  | 1.8 | 4         |
| 140 | Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1198-1206.                  | 0.6 | 6         |
| 141 | ATR-FTIR spectroscopy shows changes in ovarian cancer cells after incubation with novel organoamidoplatinum complexes. <i>Analyst, The</i> , 2018, 143, 6087-6094.  | 1.7 | 19        |
| 142 | Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application. , 0, , .   |     | 1         |
| 143 | Significant Tumor Response to the Poly (ADP-ribose) Polymerase Inhibitor Olaparib in Heavily Pretreated Patient With Ovarian Carcinosarcoma Harboring a Germline RAD51D Mutation. <i>JCO Precision Oncology</i> , 2018, 2, 1-4. | 1.5 | 14        |
| 144 | Reversal of Bowel Obstruction With Platinum-Based Chemotherapy and Olaparib in Recurrent, Short Platinum-Free Interval, RAD51C Germline Mutation-Associated Ovarian Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-8.       | 1.5 | 5         |
| 145 | Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2018, 26, 91-93.               | 0.3 | 8         |
| 146 | Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. <i>Cell Reports</i> , 2018, 25, 2617-2633.  | 2.9 | 74        |
| 147 | Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 1219-1228.               | 0.5 | 30        |
| 148 | Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients. <i>Cancers</i> , 2018, 10, 442.   | 1.7 | 30        |
| 149 | Clinical Utility of Poly (ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer. <i>Journal of Cancer Science &amp; Therapy</i> , 2018, 10, .   | 1.7 | 0         |
| 150 | How safe is rucaparib in ovarian cancer?. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1249-1255.   | 1.0 | 1         |
| 151 | Targeted treatment of advanced ovarian cancer: spotlight on rucaparib. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2189-2201.   | 0.9 | 8         |
| 152 | Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. <i>PLoS ONE</i> , 2018, 13, e0207399.   | 1.1 | 24        |
| 153 | Management and Treatment of Recurrent Epithelial Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 965-982.   | 0.9 | 40        |
| 154 | Living Through Ovarian Cancer Treatment. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1073-1085.   | 0.9 | 4         |
| 155 | Currently Approved Poly (Adenosine Diphosphate-Ribose) Inhibitors in Ovarian Cancer: Current Status and Future Directions. <i>Clinical Cancer Drugs</i> , 2018, 5, 3-12.  | 0.3 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 156 | RAD-ical New Insights into RAD51 Regulation. <i>Genes</i> , 2018, 9, 629.  | 1.0 | 98        |
| 157 | Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. <i>Cancers</i> , 2018, 10, 506.  | 1.7 | 40        |
| 158 | Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. <i>Cancers</i> , 2018, 10, 487.   | 1.7 | 154       |
| 159 | Development of PARP and Immune-Checkpoint Inhibitor Combinations. <i>Cancer Research</i> , 2018, 78, 6717-6725.  | 0.4 | 155       |
| 160 | Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2018, 16, 108-117.   | 0.2 | 0         |
| 161 | PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. <i>Cell Reports</i> , 2018, 25, 2972-2980.e5.  | 2.9 | 381       |
| 162 | Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 1.  | 1.3 | 49        |
| 163 | Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1057-1071.   | 0.9 | 5         |
| 164 | Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 6691-6702.  | 0.4 | 36        |
| 165 | Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , 2018, 9, 3970.  | 5.8 | 192       |
| 166 | Defective DNA repair in hereditary ovarian cancers: Implications for therapy. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1697-1707.   | 0.5 | 4         |
| 167 | Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3013-3019. | 2.0 | 26        |
| 168 | Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 59-78.   | 1.0 | 205       |
| 169 | Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. <i>British Journal of Cancer</i> , 2018, 119, 1401-1409.   | 2.9 | 175       |
| 170 | Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. <i>Clinics</i> , 2018, 73, e450s.  | 0.6 | 100       |
| 171 | Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2018, 119, 1060-1066.   | 2.9 | 47        |
| 172 | Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3249.  | 1.8 | 7         |
| 173 | Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in <i>BAP1</i> or other DNA repair genes. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 573-583.   | 1.5 | 43        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 174 | Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use. <i>Minerva Obstetrics and Gynecology</i> , 2018, 70, 150-170.   | 0.5  | 19        |
| 175 | A contemporary review of male breast cancer: current evidence and unanswered questions. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 599-614.  | 2.7  | 63        |
| 176 | Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. <i>Cancer Treatment Reviews</i> , 2018, 71, 1-7.                         | 3.4  | 91        |
| 177 | Surgical and Medical Management of Epithelial Ovarian Cancer. , 2018, , 884-904.   |      | 0         |
| 178 | Multiline treatment combining apatinib with topotecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1989-1995.            | 1.0  | 5         |
| 179 | Novel Systemic Treatments in High Grade Ovarian Cancer. , 0, , .   |      | 0         |
| 180 | Safety and dose modification for patients receiving niraparib. <i>Annals of Oncology</i> , 2018, 29, 1784-1792.  | 0.6  | 125       |
| 181 | New Therapies for Ovarian Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 632-635.  | 2.3  | 8         |
| 182 | Biomarkers for Homologous Recombination Deficiency in Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 704-713.  | 3.0  | 223       |
| 183 | A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 4482-4493.                     | 3.2  | 91        |
| 184 | The role of niraparib for the treatment of ovarian cancer. <i>Future Oncology</i> , 2018, 14, 2565-2577.   | 1.1  | 10        |
| 185 | Synthetic lethal therapies for cancer: what's next after PARP inhibitors?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 564-576.  | 12.5 | 303       |
| 186 | Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 686-702. | 1.2  | 149       |
| 187 | Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 600-611.   | 1.2  | 18        |
| 188 | Personalising Treatment for High-Grade Serous Ovarian Carcinoma. <i>Clinical Oncology</i> , 2018, 30, 515-524.   | 0.6  | 16        |
| 189 | Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls. <i>Journal of Molecular Biology</i> , 2018, 430, 2900-2912.   | 2.0  | 21        |
| 190 | Metastatic gynecologic malignancies: advances in treatment and management. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 521-533.  | 1.7  | 11        |
| 191 | Emerging Molecular Targets for Anti-Cancer Drug Design. <i>Current Chemical Biology</i> , 2018, 12, 88-99.   | 0.2  | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 192 | PARP Inhibitors in Epithelial Ovarian Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 145-158.  | 0.8 | 35        |
| 193 | Inherent and toxicant-provoked reduction in DNA repair capacity: A key mechanism for personalized risk assessment, cancer prevention and intervention, and response to therapy. <i>International Journal of Hygiene and Environmental Health</i> , 2018, 221, 993-1006. | 2.1 | 13        |
| 194 | Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877848.   | 1.4 | 23        |
| 195 | PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. <i>Current Drug Targets</i> , 2018, 19, 21-37.   | 1.0 | 100       |
| 196 | Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878665.  | 1.4 | 105       |
| 197 | Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. <i>Molecular Cancer Research</i> , 2018, 16, 1103-1111.                       | 1.5 | 83        |
| 198 | Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 1366-1376.   | 0.6 | 101       |
| 199 | Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. <i>Cancer Medicine</i> , 2018, 7, 2360-2369.   | 1.3 | 16        |
| 200 | Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1501-1509.  | 2.0 | 27        |
| 201 | Rucaparib: a novel PARP inhibitor for <i>BRCA</i> and advanced ovarian cancer. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 605-617.  | 2.0 | 26        |
| 202 | Copy number signatures and mutational processes in ovarian carcinoma. <i>Nature Genetics</i> , 2018, 50, 1262-1270.   | 9.4 | 320       |
| 203 | Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. <i>Clinical Cancer Research</i> , 2018, 24, 6204-6211.   | 3.2 | 61        |
| 204 | Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 16.   | 0.7 | 123       |
| 205 | Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. <i>Future Oncology</i> , 2018, 14, 3101-3110.   | 1.1 | 10        |
| 206 | BRCAness and prostate cancer: diagnostic and therapeutic considerations. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 488-498.   | 2.0 | 12        |
| 207 | Emerging therapeutic modalities of PARP inhibitors in breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 68, 62-68.   | 3.4 | 28        |
| 208 | Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?. <i>Cancer Treatment Reviews</i> , 2018, 69, 53-65.  | 3.4 | 30        |
| 209 | Origins based clinical and molecular complexities of epithelial ovarian cancer. <i>International Journal of Biological Macromolecules</i> , 2018, 118, 1326-1345.   | 3.6 | 21        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 210 | Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 2019, 29, 29-39.   | 2.3 | 43        |
| 211 | PARP Inhibition to Enhance Response to Chemotherapy. , 2019, , 231-257.   |     | 1         |
| 212 | Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors. Clinical Pharmacology in Drug Development, 2019, 8, 107-118.   | 0.8 | 30        |
| 213 | Implementing precision cancer medicine in the genomic era. Seminars in Cancer Biology, 2019, 55, 16-27.   | 4.3 | 24        |
| 214 | Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. Expert Opinion on Therapeutic Targets, 2019, 23, 773-785.                           | 1.5 | 22        |
| 215 | Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting. Gynecologic Oncology Reports, 2019, 29, 123-125.   | 0.3 | 3         |
| 216 | Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer. Journal of Clinical Oncology, 2019, 37, 2424-2436.  | 0.8 | 29        |
| 217 | The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers. Journal of Clinical Oncology, 2019, 37, 2449-2459.   | 0.8 | 13        |
| 218 | Update on Genetic Testing in Gynecologic Cancer. Journal of Clinical Oncology, 2019, 37, 2501-2509.   | 0.8 | 26        |
| 219 | Diverse mechanisms of PARP inhibitor resistance in ovarian cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 188307.  | 3.3 | 14        |
| 220 | Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors. Current Oncology Reports, 2019, 21, 83.  | 1.8 | 22        |
| 221 | Site-specific analysis of the Asp- and Glu-ADP-ribosylated proteome by quantitative mass spectrometry. Methods in Enzymology, 2019, 626, 301-321.                                     | 0.4 | 9         |
| 222 | Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. Translational Oncology, 2019, 12, 1386-1394.           | 1.7 | 7         |
| 223 | &lt;p&gt;Evidence to date: talazoparib in the treatment of breast cancer&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 5177-5187.  | 1.0 | 30        |
| 224 | Overcoming Resistance to PARP Inhibition. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 161-189.   | 0.1 | 0         |
| 226 | Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. International Journal of Gynecological Cancer, 2019, 29, 956-968. | 1.2 | 4         |
| 227 | PARP-1 and its associated nucleases in DNA damage response. DNA Repair, 2019, 81, 102651.   | 1.3 | 122       |
| 228 | Fallopian Tube Carcinoma. Journal of Oncology Practice, 2019, 15, 375-382.  | 2.5 | 28        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 229 | The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report. Journal of Gynecologic Oncology, 2019, 30, e91.  | 1.0  | 5         |
| 230 | Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. International Journal of Molecular Sciences, 2019, 20, 3100. | 1.8  | 32        |
| 232 | PARP Inhibition in Cancer: An Update on Clinical Development. Targeted Oncology, 2019, 14, 657-679.  | 1.7  | 133       |
| 233 | ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer. Nature Communications, 2019, 10, 4632.  | 5.8  | 21        |
| 235 | Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review. Journal of Ovarian Research, 2019, 12, 103.   | 1.3  | 68        |
| 236 | Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility. Gynecologic Oncology, 2019, 155, 473-482.   | 0.6  | 3         |
| 237 | Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. Expert Opinion on Investigational Drugs, 2019, 28, 771-785.   | 1.9  | 9         |
| 238 | Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies. Frontiers in Pharmacology, 2019, 10, 426.   | 1.6  | 21        |
| 239 | PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology, 2019, 155, 144-150.   | 0.6  | 28        |
| 240 | Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization. Lung Cancer, 2019, 137, 48-51.   | 0.9  | 22        |
| 241 | Prospects for combining immune checkpoint blockade with PARP inhibition. Journal of Hematology and Oncology, 2019, 12, 98.   | 6.9  | 92        |
| 242 | Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2403-2415.  | 13.9 | 627       |
| 243 | Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer, 2019, 19, 901.   | 1.1  | 33        |
| 244 | Prevalence of germline pathogenic <i>BRCA1/2</i> variants in sequential epithelial ovarian cancer cases. Journal of Medical Genetics, 2019, 56, 301-307.   | 1.5  | 21        |
| 245 | 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecologic Oncology, 2019, 153, 127-134.  | 0.6  | 56        |
| 246 | Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. Journal of Ovarian Research, 2019, 12, 9.                                      | 1.3  | 83        |
| 247 | Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. International Journal of Cancer, 2019, 145, 1209-1220.   | 2.3  | 23        |
| 248 | PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. Journal of Cellular and Molecular Medicine, 2019, 23, 2303-2313.  | 1.6  | 103       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 249 | Ovarian Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 67-88.   | 0.7 | 12        |
| 250 | Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 137-154.   | 0.7 | 3         |
| 251 | Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 12-17.   | 0.9 | 7         |
| 253 | A decade of clinical development of PARP inhibitors in perspective. <i>Annals of Oncology</i> , 2019, 30, 1437-1447.   | 0.6 | 437       |
| 254 | Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. <i>ESMO Open</i> , 2019, 4, e000480.  | 2.0 | 47        |
| 255 | Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". <i>Pharmacoeconomics</i> , 2019, 37, 1065-1067.  | 1.7 | 6         |
| 256 | Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers. <i>Methods in Molecular Biology</i> , 2019, 1999, 3-29.  | 0.4 | 3         |
| 257 | Ovarian cancer relapse: From the latest scientific evidence to the best practice. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 28-38.   | 2.0 | 31        |
| 258 | Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 39-51. | 2.0 | 11        |
| 259 | Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations. <i>BMC Cancer</i> , 2019, 19, 535.   | 1.1 | 77        |
| 260 | PARP Inhibitors in Ovarian Cancer: The Route to "Diagnostics". <i>Diagnosics</i> , 2019, 9, 55.  | 1.3 | 52        |
| 261 | Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes. <i>BMC Cancer</i> , 2019, 19, 422.   | 1.1 | 22        |
| 262 | Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. <i>Genetics and Molecular Biology</i> , 2019, 42, 215-231.  | 0.6 | 14        |
| 263 | Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. <i>Targeted Oncology</i> , 2019, 14, 269-283.   | 1.7 | 8         |
| 264 | The DNA Damaging Revolution: PARP Inhibitors and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 185-195.   | 1.8 | 144       |
| 265 | Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e152-e166.   | 1.8 | 12        |
| 266 | Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.  | 1.5 | 20        |
| 267 | The Drug-Diagnostic Codevelopment Model. , 2019, , 11-25.  |     | 0         |

| #   | ARTICLE  | IF    | CITATIONS |
|-----|--|-------|-----------|
| 268 | Companion Diagnostics Assay Developmentâ€”Prototype, Verification, and Analytical Validation. , 2019, , 243-263.   |       | 0         |
| 269 | <p>Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer</p>. Cancer Management and Research, 2019, Volume 11, 4371-4390.  | 0.9   | 77        |
| 270 | Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precision Oncology, 2019, 3, 1-23.  | 1.5   | 63        |
| 271 | Epithelial ovarian cancer: Evolution of management in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2019, 69, 280-304.  | 157.7 | 821       |
| 272 | Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. Scientific Reports, 2019, 9, 6314.  | 1.6   | 33        |
| 273 | ESMOâ€”ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology, 2019, 30, 672-705.   | 0.6   | 665       |
| 274 | ESMOâ€”ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. International Journal of Gynecological Cancer, 2019, 29, 728-760.                              | 1.2   | 167       |
| 275 | Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients. International Journal of Gynecological Cancer, 2019, 29, 325-333.   | 1.2   | 13        |
| 276 | Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. Biochemical Pharmacology, 2019, 167, 133-148.  | 2.0   | 19        |
| 277 | Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Annals of Oncology, 2019, 30, 721-732.  | 0.6   | 53        |
| 278 | Ovarian Cancer Maintenance: Practiceâ€”Changing Data Calls for Changing Practice. Oncologist, 2019, 24, 576-579.   | 1.9   | 0         |
| 279 | Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. International Journal of Biological Sciences, 2019, 15, 962-972.  | 2.6   | 10        |
| 280 | Cancer Treatment in the Genomic Era. Annual Review of Biochemistry, 2019, 88, 247-280.   | 5.0   | 24        |
| 281 | PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review. BioDrugs, 2019, 33, 255-273.  | 2.2   | 31        |
| 282 | Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer, 2019, 125, 1963-1972.   | 2.0   | 39        |
| 283 | RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination. DNA Repair, 2019, 76, 99-107.   | 1.3   | 13        |
| 284 | Rucaparib: A Review in Ovarian Cancer. Targeted Oncology, 2019, 14, 237-246.   | 1.7   | 26        |
| 285 | Analysis of BRCAness with multiplex ligation-dependent probe amplification using formalin-fixed and paraffin-embedded pancreatic ductal adenocarcinoma tissue obtained via endoscopic ultrasound-guided fine-needle aspiration biopsy. Pancreatology, 2019, 19, 419-423. | 0.5   | 3         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 286 | Epithelial ovarian cancer. <i>Lancet</i> , The, 2019, 393, 1240-1253.  | 6.3 | 1,039     |
| 287 | Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. <i>Cancers</i> , 2019, 11, 416.   | 1.7 | 49        |
| 288 | Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. <i>Current Oncology Reports</i> , 2019, 21, 42.  | 1.8 | 15        |
| 289 | Genetic predisposition for malignant mesothelioma: A concise review. <i>Mutation Research - Reviews in Mutation Research</i> , 2019, 781, 1-10.  | 2.4 | 30        |
| 290 | Olaparib and Î±-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 570-580. | 5.1 | 191       |
| 291 | Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.                         | 0.8 | 9         |
| 292 | New and Novel Therapies for Gynecologic Cancers. <i>Seminars in Oncology Nursing</i> , 2019, 35, 217-219.  | 0.7 | 10        |
| 293 | Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types. <i>Cancers</i> , 2019, 11, 354.   | 1.7 | 12        |
| 294 | Subcellular compartmentalization of NAD <sup>+</sup> and its role in cancer: A sereneNADE of metabolic melodies. , 2019, 200, 27-41.   |     | 53        |
| 295 | Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. <i>ESMO Open</i> , 2019, 4, e000444.   | 2.0 | 8         |
| 296 | Rucaparib in the landscape of PARP inhibition in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 437-446.   | 1.1 | 2         |
| 297 | Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. <i>Clinical Cancer Research</i> , 2019, 25, 5441-5448.                        | 3.2 | 217       |
| 298 | The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 166-173.                      | 1.2 | 17        |
| 299 | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. <i>Journal of Clinical Medicine</i> , 2019, 8, 435.  | 1.0 | 106       |
| 300 | Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. <i>Endocrine Connections</i> , 2019, 8, R10-R26.   | 0.8 | 33        |
| 301 | ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. <i>Gynecologic Oncology</i> , 2019, 153, 416-424.                | 0.6 | 26        |
| 302 | Integrated structural variation and point mutation signatures in cancer genomes using correlated topic models. <i>PLoS Computational Biology</i> , 2019, 15, e1006799.                               | 1.5 | 44        |
| 303 | An Advanced Strategy for Comprehensive Profiling of ADP-ribosylation Sites Using Mass Spectrometry-based Proteomics*. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1010a-1026.               | 2.5 | 113       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 304 | Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2019, 153, 217-222.  | 0.6 | 38        |
| 305 | The role of dePARylation in DNA damage repair and cancer suppression. <i>DNA Repair</i> , 2019, 76, 20-29.  | 1.3 | 7         |
| 306 | Major clinical research advances in gynecologic cancer in 2018. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e18.   | 1.0 | 29        |
| 307 | Homologous recombination deficiency in triple negative breast cancer. <i>Breast</i> , 2019, 45, 15-21.  | 0.9 | 58        |
| 308 | Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 11-25.  | 0.4 | 1         |
| 309 | Treatment of recurrent epithelial ovarian cancer. <i>Cancer</i> , 2019, 125, 4609-4615.   | 2.0 | 49        |
| 310 | Pan-Cancer Analysis of <i>CDK12</i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. <i>Oncologist</i> , 2019, 24, 1526-1533.   | 1.9 | 39        |
| 311 | Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i> -mutated, high-grade ovarian cancer, and an update on safety. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1396-1404. | 1.2 | 19        |
| 312 | Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review. <i>Asian Journal of Oncology</i> , 2019, 05, 01-18.  | 0.2 | 0         |
| 313 | Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. <i>BMJ Case Reports</i> , 2019, 12, e230738.  | 0.2 | 18        |
| 314 | Advances and perspectives of PARP inhibitors. <i>Experimental Hematology and Oncology</i> , 2019, 8, 29.  | 2.0 | 81        |
| 315 | Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1097.   | 1.3 | 13        |
| 316 | Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. <i>Cancers</i> , 2019, 11, 1980.  | 1.7 | 29        |
| 317 | Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 554-561.  | 0.7 | 2         |
| 318 | Clinical Applications of Next-Generation Sequencing in Precision Oncology. <i>Cancer Journal (Sudbury, Tj ETQq0 0 0 jgBT /Overlock 10 Tf</i>  | 1.0 | 21        |
| 319 | Current role of poly(ADP-ribose) polymerase inhibitors. <i>Current Opinion in Oncology</i> , 2019, 31, 394-403.   | 1.1 | 2         |
| 320 | Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.   | 1.5 | 0         |
| 321 | Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?. <i>Gynecologic Oncology</i> , 2019, 152, 3-6.  | 0.6 | 1         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 322 | Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 198-213.           | 1.2  | 2         |
| 323 | Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. <i>Journal of Medical Economics</i> , 2019, 22, 187-195.  | 1.0  | 7         |
| 324 | Exploring and comparing adverse events between PARP inhibitors. <i>Lancet Oncology</i> , The, 2019, 20, e15-e28.  | 5.1  | 287       |
| 325 | EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 819-829.  | 0.4  | 52        |
| 326 | Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2019, 152, 416-425.   | 0.6  | 31        |
| 327 | Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 1087-1097.   | 3.2  | 113       |
| 328 | Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer. , 2019, , 521-532.   |      | 2         |
| 329 | New Treatment Options for Ovarian Cancer. , 2019, , 533-540.  |      | 0         |
| 330 | Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 371-378.  | 1.1  | 37        |
| 331 | <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 210-219.   | 7.7  | 278       |
| 332 | Evaluation of Drug-Drug Interactions of Rucaparib and <i>CYP</i> 1A2, <i>CYP</i> 2C9, <i>CYP</i> 2C19, <i>CYP</i> 3A, and <i>P-gp</i> Substrates in Patients With an Advanced Solid Tumor. <i>Clinical and Translational Science</i> , 2019, 12, 58-65. | 1.5  | 17        |
| 333 | Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 171-182.                                | 2.0  | 93        |
| 334 | Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 697-706.   | 0.8  | 3         |
| 335 | Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors. <i>Biochemical Pharmacology</i> , 2019, 167, 125-132.   | 2.0  | 9         |
| 336 | State-of-the-art strategies for targeting the DNA damage response in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 81-104.  | 12.5 | 736       |
| 338 | PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2019, 10, 337-345.   | 0.5  | 25        |
| 339 | The Fanconi Anemia Pathway in Cancer. <i>Annual Review of Cancer Biology</i> , 2019, 3, 457-478.  | 2.3  | 261       |
| 340 | Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOc) patients. <i>Gynecologic Oncology</i> , 2019, 152, 270-277.   | 0.6  | 12        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 341 | PARP inhibitors in ovarian cancer. <i>Cancer Treatment Reviews</i> , 2019, 73, 1-9.  | 3.4 | 158       |
| 342 | Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer. <i>Journal of Pharmacy Practice</i> , 2019, 32, 219-224.  | 0.5 | 4         |
| 343 | Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. <i>Oncologist</i> , 2020, 25, e109-e119.  | 1.9 | 13        |
| 344 | Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. <i>Gynecologic Oncology</i> , 2020, 156, 488-497.   | 0.6 | 51        |
| 345 | PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. <i>Cancer Letters</i> , 2020, 469, 124-133.   | 3.2 | 22        |
| 346 | Genetic Factors. , 2020, , 180-208.e11.  |     | 4         |
| 347 | Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 3-11.   | 1.3 | 5         |
| 348 | PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 718-729.  | 0.5 | 13        |
| 349 | Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. <i>Gynecologic Oncology</i> , 2020, 156, 517-522.   | 0.6 | 16        |
| 350 | Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. <i>Translational Oncology</i> , 2020, 13, 410-422.   | 1.7 | 52        |
| 351 | Latest clinical evidence of maintenance therapy in ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 15-21.  | 0.9 | 19        |
| 352 | Prediction of Epithelial Ovarian Cancer Outcomes With Integration of Genomic Data. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 92-108.   | 0.6 | 6         |
| 353 | A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , 2020, 26, 1372-1384.  | 3.2 | 66        |
| 354 | Biomarkers that may predict response to immunotherapy in ovarian malignancies. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 84-90.  | 0.9 | 8         |
| 355 | Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. <i>Human Mutation</i> , 2020, 41, 696-708.   | 1.1 | 21        |
| 356 | Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> . 2020. 476. 195-207. | 1.4 | 12        |
| 357 | An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 222-232.  | 0.6 | 37        |
| 358 | P5 eHealth: An Agenda for the Health Technologies of the Future. , 2020, , .   |     | 21        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 359 | Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. <i>Gynecologic Oncology</i> , 2020, 156, 415-422.     | 0.6 | 28        |
| 360 | Recent advancements in PARP inhibitors-based targeted cancer therapy. <i>Precision Clinical Medicine</i> , 2020, 3, 187-201.   | 1.3 | 26        |
| 361 | Clinical assays for assessment of homologous recombination DNA repair deficiency. <i>Gynecologic Oncology</i> , 2020, 159, 887-898.  | 0.6 | 70        |
| 362 | Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. <i>Journal of Clinical Pathology</i> , 2020, 74, jclinpath-2020-206800.                               | 1.0 | 3         |
| 363 | New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 578095.  | 1.3 | 36        |
| 364 | Newly diagnosed ovarian cancer: Which first-line treatment?. <i>Cancer Treatment Reviews</i> , 2020, 91, 102111.   | 3.4 | 23        |
| 365 | Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy. <i>International Journal of Pharmaceutics</i> , 2020, 591, 119986.   | 2.6 | 30        |
| 366 | Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. <i>Life Sciences</i> , 2020, 261, 118434.  | 2.0 | 23        |
| 367 | The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 1002-1013.                                      | 1.4 | 18        |
| 368 | &lt;p&gt;Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9857-9863.  | 1.0 | 10        |
| 369 | ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. <i>Annals of Oncology</i> , 2020, 31, 1606-1622.  | 0.6 | 238       |
| 370 | The DNA damaging revolution. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103117.   | 2.0 | 9         |
| 371 | Homologous recombination deficiency real-time clinical assays, ready or not?. <i>Gynecologic Oncology</i> , 2020, 159, 877-886.  | 0.6 | 39        |
| 372 | Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA. <i>Oncogene</i> , 2020, 39, 7051-7062.   | 2.6 | 18        |
| 373 | Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1977-1986.   | 0.5 | 5         |
| 374 | Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system. <i>Gynecologic Oncology</i> , 2020, 158, 747-753. | 0.6 | 12        |
| 375 | Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. <i>European Journal of Human Genetics</i> , 2020, 28, 1541-1547.  | 1.4 | 22        |
| 376 | Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4910.   | 1.8 | 45        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 377 | The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy. <i>Heliyon</i> , 2020, 6, e03841.                                       | 1.4 | 10        |
| 379 | DNA damaging agents in ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 67-72.   | 2.2 | 2         |
| 380 | Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1 and BRCA2 mutation carriers. <i>Seminars in Cancer Biology</i> , 2020, 77, 110-126.                                | 4.3 | 16        |
| 381 | Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens. <i>Nature Communications</i> , 2020, 11, 6118.                                    | 5.8 | 39        |
| 382 | Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts. <i>Journal of Clinical Medicine</i> , 2020, 9, 2377.  | 1.0 | 1         |
| 383 | Discovery through clinical sequencing in oncology. <i>Nature Cancer</i> , 2020, 1, 774-783.   | 5.7 | 29        |
| 384 | Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters. <i>Gene</i> , 2020, 759, 145000.  | 1.0 | 9         |
| 385 | Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. <i>JCO Precision Oncology</i> , 2020, 4, 882-897.                 | 1.5 | 22        |
| 386 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 137.   | 7.1 | 79        |
| 387 | Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 159, 79-87. | 0.6 | 6         |
| 388 | BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 79.                                   | 2.2 | 8         |
| 389 | Financial Toxicity Encountered in Therapeutic Radiopharmaceutical Clinical Development for Ovarian Cancer. <i>Pharmaceuticals</i> , 2020, 13, 181.  | 1.7 | 2         |
| 390 | PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3468-3493.   | 0.8 | 175       |
| 391 | XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells. <i>NAR Cancer</i> , 2020, 2, zcaa013.   | 1.6 | 36        |
| 392 | Synthetic Lethality through the Lens of Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14151-14183.   | 2.9 | 31        |
| 393 | Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3046.   | 1.7 | 22        |
| 394 | TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.  | 0.8 | 276       |
| 396 | Anti-angiogenic therapy for ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 77-86.  | 2.2 | 8         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 397 | Poly(ADP-ribose) polymerase inhibition: past, present and future. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 711-736.  | 21.5 | 275       |
| 398 | Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. <i>Journal of Hematology and Oncology</i> , 2020, 13, 118.  | 6.9  | 95        |
| 399 | Secondary and tertiary ovarian cancer recurrence: what is the best management?. <i>Gland Surgery</i> , 2020, 9, 1118-1129.   | 0.5  | 18        |
| 400 | Development of new medical treatment for epithelial ovarian cancer recurrence. <i>Gland Surgery</i> , 2020, 9, 1149-1163.  | 0.5  | 12        |
| 401 | <i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1190-1203.   | 3.0  | 32        |
| 402 | The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1608-1618.   | 1.2  | 4         |
| 403 | PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies. <i>Chinese Clinical Oncology</i> , 2020, 9, 51-51.   | 0.4  | 4         |
| 404 | A new targeted treatment for patients with a germline <i>BRCA</i> mutation: olaparib in pancreatic cancer. <i>Future Oncology</i> , 2020, 16, 2691-2700.   | 1.1  | 1         |
| 405 | Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?. <i>Current Opinion in Oncology</i> , 2020, 32, 442-450.   | 1.1  | 10        |
| 406 | Front-Line Maintenance Therapy in Advanced Ovarian Cancer – Current Advances and Perspectives. <i>Cancers</i> , 2020, 12, 2414.  | 1.7  | 10        |
| 407 | Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 1087-1102.  | 0.8  | 31        |
| 408 | BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. <i>EBioMedicine</i> , 2020, 60, 102988.   | 2.7  | 27        |
| 409 | Breast cancer (BRCA) gene testing in ovarian cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 63-63.  | 0.4  | 3         |
| 410 | &lt;p&gt;Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5561-5571. | 3.3  | 8         |
| 411 | Molecular Features and Clinical Management of Hereditary Gynecological Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9504.   | 1.8  | 13        |
| 412 | BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9708.  | 1.8  | 17        |
| 413 | Treatment of Recurrent Epithelial Ovarian Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1195-1204.   | 0.8  | 13        |
| 414 | Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets. <i>Seminars in Cancer Biology</i> , 2021, 77, 29-41.  | 4.3  | 27        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 415 | Targeted Molecular Therapy in Palliative Cancer Management. , 2020, 5, .   |     | 1         |
| 416 | Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4135-4142.  | 3.2 | 95        |
| 417 | BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. <i>Journal of Ovarian Research</i> , 2020, 13, 50.  | 1.3 | 64        |
| 418 | PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e116-e131. | 1.8 | 30        |
| 419 | Therapeutic applications of PARP inhibitors in ovarian cancer. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110204.   | 2.5 | 29        |
| 420 | &lt;p&gt;BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 2731-2742.   | 0.9 | 69        |
| 421 | Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. <i>JCO Precision Oncology</i> , 2020, 4, 442-465.   | 1.5 | 103       |
| 422 | Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.   | 3.2 | 126       |
| 423 | Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 491-502.   | 1.1 | 2         |
| 424 | Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1206.   | 1.7 | 6         |
| 425 | Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. <i>Gynecologic Oncology</i> , 2020, 158, 16-24.   | 0.6 | 40        |
| 426 | Biomarker-Guided Development of DNA Repair Inhibitors. <i>Molecular Cell</i> , 2020, 78, 1070-1085.  | 4.5 | 157       |
| 427 | Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. <i>Nature Communications</i> , 2020, 11, 2662.   | 5.8 | 157       |
| 428 | CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. <i>Nature Communications</i> , 2020, 11, 2641.  | 5.8 | 90        |
| 429 | Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492.   | 5.7 | 23        |
| 430 | PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. <i>Cancers</i> , 2020, 12, 1378.  | 1.7 | 29        |
| 431 | HRness in Breast and Ovarian Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3850.   | 1.8 | 14        |
| 432 | Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 165-188.  | 1.0 | 10        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 433 | Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. Targeted Oncology, 2020, 15, 391-406.  | 1.7 | 11        |
| 434 | Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092198.  | 1.4 | 8         |
| 435 | The forefront of ovarian cancer therapy: update on PARP inhibitors. Annals of Oncology, 2020, 31, 1148-1159.  | 0.6 | 191       |
| 436 | The emerging role of precision medicine in the treatment of ovarian cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 283-297.   | 0.4 | 3         |
| 437 | Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells, 2020, 9, 1402.   | 1.8 | 46        |
| 438 | Wnt Signaling in Gynecologic Malignancies. International Journal of Molecular Sciences, 2020, 21, 4272.   | 1.8 | 45        |
| 439 | BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy. JNCI Cancer Spectrum, 2020, 4, plz100.   | 1.4 | 7         |
| 440 | Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. International Journal of Biological Sciences, 2020, 16, 1363-1375.  | 2.6 | 22        |
| 441 | Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. International Journal of Gynecological Cancer, 2020, 30, 684-694.  | 1.2 | 6         |
| 442 | Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells, 2020, 9, 719.   | 1.8 | 43        |
| 443 | Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. Cancers, 2020, 12, 707.   | 1.7 | 14        |
| 444 | Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Drugs in R and D, 2020, 20, 55-73.   | 1.1 | 84        |
| 445 | Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer. Theranostics, 2020, 10, 3939-3951.  | 4.6 | 35        |
| 446 | Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. BMC Cancer, 2020, 20, 204.  | 1.1 | 25        |
| 447 | The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity. Cancers, 2020, 12, 564.  | 1.7 | 12        |
| 448 | Evaluation of <i>in vitro</i> absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor. Xenobiotica, 2020, 50, 1032-1042. | 0.5 | 25        |
| 449 | Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer. Frontiers in Oncology, 2020, 10, 958.  | 1.3 | 9         |
| 450 | Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer. Frontiers in Oncology, 2020, 10, 954.   | 1.3 | 8         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 451 | The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 151.               | 0.8  | 14        |
| 453 | PARP and PARC inhibitors in cancer treatment. <i>Genes and Development</i> , 2020, 34, 360-394.  | 2.7  | 360       |
| 454 | Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing. <i>BioMed Research International</i> , 2020, 2020, 1-10.   | 0.9  | 7         |
| 455 | PARP inhibitors: a tsunami of indications in different malignancies. <i>Pharmacogenomics</i> , 2020, 21, 221-230.  | 0.6  | 16        |
| 456 | A profile on the FoundationFocus CDxBRCA tests. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 285-292.   | 1.5  | 15        |
| 457 | PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?. <i>Current Oncology Reports</i> , 2020, 22, 29.   | 1.8  | 14        |
| 458 | The kinase polypharmacology landscape of clinical PARP inhibitors. <i>Scientific Reports</i> , 2020, 10, 2585.   | 1.6  | 68        |
| 459 | Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1164-1174. | 0.8  | 194       |
| 460 | The antitumorigenic roles of BRCA1 and BARD1 in DNA repair and replication. <i>Nature Reviews Molecular Cell Biology</i> , 2020, 21, 284-299.  | 16.1 | 199       |
| 461 | CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. <i>Gynecologic Oncology</i> , 2020, 157, 405-410.   | 0.6  | 30        |
| 462 | A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 214-221.                  | 0.6  | 2         |
| 463 | Enabling Precision Oncology Through Precision Diagnostics. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 97-121.  | 9.6  | 50        |
| 464 | Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1222-1245.  | 0.8  | 202       |
| 465 | Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer. <i>Cancer Medicine</i> , 2020, 9, 2190-2200.  | 1.3  | 27        |
| 466 | Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102888.                              | 2.0  | 13        |
| 467 | Higher prevalence of homologous recombination deficiency in tumors from African Americans versus European Americans. <i>Nature Cancer</i> , 2020, 1, 112-121.  | 5.7  | 30        |
| 468 | Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?. <i>Current Treatment Options in Oncology</i> , 2020, 21, 49.   | 1.3  | 7         |
| 469 | The tubal epigenome – An emerging target for ovarian cancer. , 2020, 210, 107524.  |      | 10        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 470 | Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 157, 500-507.  | 0.6 | 23        |
| 471 | Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 509-514. | 1.2 | 9         |
| 472 | Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 903-915.   | 1.2 | 52        |
| 473 | Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. <i>Cancers</i> , 2020, 12, 972.  | 1.7 | 14        |
| 474 | BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 323-329.  | 1.1 | 9         |
| 475 | Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 222-231.  | 0.7 | 8         |
| 476 | The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. <i>Annals of Surgical Oncology</i> , 2020, 27, 1780-1787.  | 0.7 | 13        |
| 477 | Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 160.  | 1.8 | 46        |
| 478 | The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. <i>Cancer</i> , 2020, 126, 2553-2560.  | 2.0 | 11        |
| 479 | The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 231-241.  | 1.7 | 3         |
| 480 | Parthanatos and its associated components: Promising therapeutic targets for cancer. <i>Pharmacological Research</i> , 2021, 163, 105299.   | 3.1 | 50        |
| 481 | PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 485-493.   | 1.1 | 23        |
| 482 | Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program. <i>Molecular Oncology</i> , 2021, 15, 80-90.   | 2.1 | 14        |
| 483 | Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. <i>Modern Pathology</i> , 2021, 34, 983-993.  | 2.9 | 11        |
| 484 | The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 333-345.   | 0.6 | 40        |
| 485 | Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. <i>Oncologist</i> , 2021, 26, e394-e402.   | 1.9 | 39        |
| 486 | Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103145. | 2.0 | 34        |
| 487 | Current Ovarian Cancer Maintenance Strategies and Promising New Developments. <i>Journal of Cancer</i> , 2021, 12, 38-53.   | 1.2 | 36        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 489 | PARP inhibitors and the Kidney. <i>Journal of Onco-Nephrology</i> , 2021, 5, 42-47.  | 0.3 | 4         |
| 490 | Comments on: Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e33.  | 1.0 | 0         |
| 491 | DNA Damage Repair Inhibitor for Breast Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 159-179.   | 0.8 | 0         |
| 492 | Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells. <i>Cancer Research</i> , 2021, 81, 2774-2787.   | 0.4 | 17        |
| 493 | Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. <i>Experimental and Molecular Medicine</i> , 2021, 53, 42-51.   | 3.2 | 93        |
| 494 | How to sequence treatment in relapsed ovarian cancer. <i>Future Oncology</i> , 2021, 17, 1-8.  | 1.1 | 1         |
| 495 | Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1330, 1-19.   | 0.8 | 1         |
| 496 | Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids. , 2021, , .   |     | 0         |
| 497 | Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors. <i>Journal of Genetic Counseling</i> , 2021, 30, 342-360. | 0.9 | 18        |
| 498 | The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 869-877.                                 | 1.1 | 2         |
| 499 | Next-generation sequencing: an expedition from workstation to clinical applications. , 2021, , 29-47.  |     | 5         |
| 500 | Text Analytics and Mixed Feature Extraction in Ovarian Cancer Clinical and Genetic Data. <i>IEEE Access</i> , 2021, 9, 58034-58051.  | 2.6 | 2         |
| 501 | PARP inhibitors in ovarian cancer: An overview of the practice—changing trials. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 385-397.   | 1.5 | 51        |
| 502 | Homologous recombination repair deficiency (HRD): From biology to clinical exploitation. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 299-302.  | 1.5 | 16        |
| 503 | Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. <i>Seminars in Cancer Biology</i> , 2021, 77, 67-82.   | 4.3 | 12        |
| 504 | Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 149.   | 1.1 | 16        |
| 505 | Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors. <i>PLoS ONE</i> , 2021, 16, e0246048.  | 1.1 | 0         |
| 506 | Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. <i>Cancers</i> , 2021, 13, 1004.  | 1.7 | 28        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 508 | Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 4219.                                  | 1.6 | 37        |
| 509 | Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. <i>Cancers</i> , 2021, 13, 1420.           | 1.7 | 7         |
| 510 | Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. <i>Cancers</i> , 2021, 13, 1298.  | 1.7 | 24        |
| 511 | Long-Term Follow-Up of a Female Patient Treated with Olaparibâ€™Hope for a Long Life without Relapse?. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3430. | 1.2 | 1         |
| 512 | Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3201-3214. | 3.2 | 27        |
| 513 | Molecular disruption of DNA polymerase $\delta$ for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. <i>Oncogene</i> , 2021, 40, 2496-2508.                          | 2.6 | 12        |
| 515 | Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 543-554.                   | 1.9 | 13        |
| 516 | The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.   | 3.2 | 24        |
| 517 | Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. <i>Drug Resistance Updates</i> , 2021, 55, 100744.  | 6.5 | 43        |
| 518 | Avoid the trap: Targeting PARP1 beyond human malignancy. <i>Cell Chemical Biology</i> , 2021, 28, 456-462.  | 2.5 | 12        |
| 519 | Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. <i>Cancers</i> , 2021, 13, 2067.   | 1.7 | 7         |
| 521 | Identification of ubiquitination-related genes in human glioma as indicators of patient prognosis. <i>PLoS ONE</i> , 2021, 16, e0250239.  | 1.1 | 7         |
| 522 | FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. <i>Cancers</i> , 2021, 13, 1866.  | 1.7 | 12        |
| 523 | Genetic alterations and their therapeutic implications in epithelial ovarian cancer. <i>BMC Cancer</i> , 2021, 21, 499.   | 1.1 | 27        |
| 524 | Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.      | 5.8 | 116       |
| 527 | Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. <i>Journal of Clinical Oncology</i> , 2021, 39, 1631-1640.    | 0.8 | 62        |
| 528 | Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). <i>BMC Cancer</i> , 2021, 21, 593.          | 1.1 | 34        |
| 529 | Present and Future for PARP Inhibitors in Ovarian Cancer. <i>Advances in Oncology</i> , 2021, 1, 139-154.   | 0.1 | 0         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 530 | DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2021, 50, e50-e52.   | 0.5  | 1         |
| 531 | Poly (adenosine diphosphate [ADP]â€“ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 285-296. | 0.8  | 10        |
| 532 | Estrogen enhances the cytotoxicity of PARP inhibitors on breast cancer cells through stimulating nitric oxide production. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 209, 105853.   | 1.2  | 8         |
| 533 | PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data. <i>Oral Oncology</i> , 2021, 117, 105292.   | 0.8  | 21        |
| 534 | The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?. <i>ESMO Open</i> , 2021, 6, 100144.  | 2.0  | 77        |
| 535 | The systemic treatment of recurrent ovarian cancer revisited. <i>Annals of Oncology</i> , 2021, 32, 710-725.  | 0.6  | 61        |
| 536 | Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1102-1110.   | 0.5  | 1         |
| 537 | Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer. <i>Current Drug Targets</i> , 2022, 23, 145-155.  | 1.0  | 5         |
| 538 | Structural Chromosome Instability: Types, Origins, Consequences, and Therapeutic Opportunities. <i>Cancers</i> , 2021, 13, 3056.  | 1.7  | 26        |
| 539 | Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1013-1023.   | 1.5  | 3         |
| 540 | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. <i>Annals of Oncology</i> , 2021, 32, 757-765.  | 0.6  | 105       |
| 541 | Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 68.e1-68.e11.  | 0.7  | 10        |
| 542 | Understanding and overcoming resistance to PARP inhibitors in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 773-791.  | 12.5 | 198       |
| 543 | Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and Therapeutic Potentials. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7748.   | 1.8  | 23        |
| 544 | Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. <i>NAR Cancer</i> , 2021, 3, zcab028.   | 1.6  | 20        |
| 545 | PGK1 Is a Key Target for Anti-Glycolytic Therapy of Ovarian Cancer: Based on the Comprehensive Analysis of Glycolysis-Related Genes. <i>Frontiers in Oncology</i> , 2021, 11, 682461.   | 1.3  | 17        |
| 546 | The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 871-878.   | 2.3  | 10        |
| 547 | Tumor Treating Fields for Ovarian Carcinoma: A Modeling Study. <i>Advances in Radiation Oncology</i> , 2021, 6, 100716.   | 0.6  | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 548 | Emerging role of PARP $\alpha$ 1 and PARthanatos in ischemic stroke. <i>Journal of Neurochemistry</i> , 2022, 160, 74-87.   | 2.1 | 39        |
| 549 | Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells. <i>Cancer Research and Treatment</i> , 2021, 53, 819-828.                            | 1.3 | 5         |
| 550 | Predictive Value of HE4 in Platinum-Based Chemotherapy for Ovarian Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 703949.  | 1.3 | 2         |
| 551 | MicroRNA $\alpha$ 139 $\alpha$ 5p improves sepsis $\alpha$ induced lung injury by targeting Rho $\alpha$ kinase1. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1059.  | 0.8 | 7         |
| 552 | Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2021, 81, 4709-4722.   | 0.4 | 42        |
| 553 | Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 638295.  | 1.3 | 6         |
| 554 | The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data. <i>Clinical Breast Cancer</i> , 2022, 22, 10-25.   | 1.1 | 7         |
| 555 | Comparative Assessment of Diagnostic Homologous Recombination Deficiency $\alpha$ Associated Mutational Signatures in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5681-5687.  | 3.2 | 18        |
| 557 | An update of new small-molecule anticancer drugs approved from 2015 to 2020. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113473.  | 2.6 | 27        |
| 558 | Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i> , <i>BRCA2</i> , or <i>PALB2</i> . <i>Journal of Clinical Oncology</i> , 2021, 39, 2497-2505. | 0.8 | 113       |
| 559 | A phase 1, open-label, drug $\alpha$ drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 887-897.                                       | 1.1 | 6         |
| 560 | The evolving role of PARP inhibitors in advanced ovarian cancer. <i>Forum of Clinical Oncology</i> , 2021, 12, 82-104.  | 0.1 | 0         |
| 561 | Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer. <i>Environmental Science and Pollution Research</i> , 2021, 28, 49491-49506.   | 2.7 | 0         |
| 562 | Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1285-1296.  | 1.5 | 8         |
| 564 | Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2021, 162, 482-495.  | 0.6 | 31        |
| 565 | Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2028-2036.e2.  | 0.3 | 17        |
| 566 | Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. <i>Gynecologic Oncology</i> , 2021, 162, 728-734.  | 0.6 | 4         |
| 567 | Molecular Pathology of Ovarian Epithelial Neoplasms. <i>Surgical Pathology Clinics</i> , 2021, 14, 415-428.   | 0.7 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 568 | Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers. <i>Gynecologic Oncology</i> , 2021, 163, 220-228.   | 0.6 | 4         |
| 569 | Ovarian Cancerâ€“Specific <i>BRCA</i> -like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569. | 3.2 | 9         |
| 570 | Targeting ARID1A mutations in cancer. <i>Cancer Treatment Reviews</i> , 2021, 100, 102287.   | 3.4 | 63        |
| 571 | PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. <i>Cancer Treatment Reviews</i> , 2021, 99, 102255.  | 3.4 | 25        |
| 572 | Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 490-497.  | 0.6 | 20        |
| 573 | Poly (ADP-ribose) polymerase-1 (PARP1) as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.. <i>Blood Advances</i> , 2021, 5, 4794-4805.  | 2.5 | 13        |
| 574 | Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. <i>Lung Cancer</i> , 2021, 161, 180-188.          | 0.9 | 14        |
| 575 | Principles of radiation therapy and chemotherapy in gynecologic cancer. , 2022, , 618-636.e1.  |     | 2         |
| 576 | Malignant diseases of the ovary, fallopian tube, and peritoneum. , 2022, , 707-753.e7.   |     | 2         |
| 577 | Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. <i>Diagnostics</i> , 2021, 11, 199.   | 1.3 | 24        |
| 578 | The role of PARP inhibitors in <i>BRCA</i> mutated pancreatic cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110148.   | 1.4 | 21        |
| 579 | The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492199628.   | 0.6 | 33        |
| 580 | Role of Next-Generation Sequencing Technologies in Personalized Medicine. , 2020, , 125-154.   |     | 13        |
| 581 | Genomic Cancer Risk Assessment. , 2020, , 187-207.   |     | 1         |
| 582 | PARP inhibition in the ovarian cancer patient: Current approvals and future directions. , 2020, 213, 107588.   |     | 7         |
| 583 | Molecular subtypes of pancreatic cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 207-220.  | 8.2 | 573       |
| 584 | Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. <i>Bioscience Reports</i> , 2020, 40, .   | 1.1 | 13        |
| 591 | Repositioning PARP inhibitors for SARSâ€“CoVâ€“2 infection(COVIDâ€“19); a new multiâ€“pronged therapy for acute respiratory distress syndrome?. <i>British Journal of Pharmacology</i> , 2020, 177, 3635-3645.                   | 2.7 | 52        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 592 | Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals. <i>Cancer Science</i> , 2020, 111, 647-657.   | 1.7 | 22        |
| 593 | Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 89-93.  | 1.2 | 30        |
| 594 | A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 2116-2126.  | 3.9 | 100       |
| 595 | XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097420.  | 1.4 | 10        |
| 596 | Genomic Alteration in Metastatic Breast Cancer and Its Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 30-43.   | 1.8 | 107       |
| 597 | Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 358-369.  | 1.8 | 8         |
| 598 | Germline mutations in pancreatic cancer and potential new therapeutic options. <i>Oncotarget</i> , 2017, 8, 73240-73257.  | 0.8 | 40        |
| 599 | Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. <i>Oncotarget</i> , 2017, 8, 43653-43661.  | 0.8 | 85        |
| 600 | Loss of <i>BRCA1</i> promotor hypermethylation in recurrent high-grade ovarian cancer. <i>Oncotarget</i> , 2017, 8, 83063-83074.  | 0.8 | 20        |
| 601 | High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. <i>Oncotarget</i> , 2017, 8, 104430-104443.  | 0.8 | 5         |
| 602 | Genomic loss of heterozygosity and survival in the REAL3 trial. <i>Oncotarget</i> , 2018, 9, 36654-36665.   | 0.8 | 13        |
| 603 | Phase I/II study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. <i>Oncotarget</i> , 2019, 10, 2855-2868.   | 0.8 | 13        |
| 604 | PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. , 2019, 2, 665-679.  |     | 20        |
| 605 | Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology. , 2019, 2, 608-617.  |     | 3         |
| 606 | Current practices on genetic testing in ovarian cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1703-1703.   | 0.7 | 7         |
| 607 | Translational research and application of basic biology to clinical trial development in GI cancers. <i>Annals of Translational Medicine</i> , 2018, 6, 164-164.  | 0.7 | 6         |
| 608 | Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?. <i>Annals of Translational Medicine</i> , 2020, 8, 1706-1706.   | 0.7 | 17        |
| 609 | Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 370-382. | 0.7 | 18        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 610 | Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. <i>Current Drug Targets</i> , 2020, 21, 167-178.  | 1.0 | 10        |
| 611 | Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 206-212.   | 0.9 | 6         |
| 612 | Hereditary ovarian cancers: state of the art. <i>Minerva Medica</i> , 2019, 110, 301-319.   | 0.3 | 15        |
| 613 | New medical approaches in advanced ovarian cancer. <i>Minerva Medica</i> , 2019, 110, 367-384.  | 0.3 | 6         |
| 614 | PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. <i>Cancers</i> , 2020, 12, 394.   | 1.7 | 91        |
| 615 | The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. <i>Cancers</i> , 2020, 12, 2805.  | 1.7 | 30        |
| 616 | Wise Management of Ovarian Cancer: On the Cutting Edge. <i>Journal of Personalized Medicine</i> , 2020, 10, 41.   | 1.1 | 51        |
| 617 | The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 157-164.   | 0.6 | 2         |
| 618 | Integration of PARP-inhibitors in ovarian cancer therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 171-182.   | 0.5 | 3         |
| 619 | Pharmacological ascorbate induces $\sim$ BRCAness $\text{\textcircled{TM}}$ and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer. <i>Oncology Letters</i> , 2020, 19, 2629-2638. | 0.8 | 8         |
| 620 | PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.   | 0.8 | 16        |
| 621 | Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 643-654.   | 0.6 | 4         |
| 622 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 380-391.                               | 2.3 | 314       |
| 623 | Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes. , 2021, , 135-166.   |     | 0         |
| 624 | Cutting-Edge Technologies for Ovarian Cancer: An Overview of the Impact of Genetic Testing, Next-Generation Sequencing, and Single-Cell Analysis. , 2021, , 203-229.  |     | 0         |
| 625 | The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers. , 2021, , 59-133.   |     | 0         |
| 626 | Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e95.   | 1.0 | 5         |
| 627 | Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics. <i>Journal of Ovarian Research</i> , 2021, 14, 140.   | 1.3 | 8         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 628 | The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 338. | 3.5 | 12        |
| 629 | Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 61-85.  | 1.0 | 145       |
| 630 | Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 246-253.                      | 0.6 | 62        |
| 631 | Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction. <i>Frontiers in Oncology</i> , 2021, 11, 675972.   | 1.3 | 21        |
| 632 | A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes. <i>Biomedicines</i> , 2021, 9, 1384.  | 1.4 | 4         |
| 633 | ATR inhibition reverses the resistance of homologous recombination deficient MGMT <sup>low</sup> /MMR <sup>proficient</sup> cancer cells to temozolomide. <i>Oncotarget</i> , 2021, 12, 2114-2130.   | 0.8 | 3         |
| 634 | Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.   | 3.4 | 44        |
| 635 | Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers. <i>Genes</i> , 2021, 12, 1593.   | 1.0 | 2         |
| 636 | Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. <i>Cancers</i> , 2021, 13, 5299.   | 1.7 | 2         |
| 637 | Poly(ADP-Ribose) Polymerase Inhibitors and Myeloid Neoplasm Risk—Clues to a Mechanistic Connection?. <i>JAMA Oncology</i> , 2021, 7, 1763.   | 3.4 | 0         |
| 639 | Gynecological Symptoms. , 2018, , 505-526.   |     | 0         |
| 641 | Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer. <i>Cureus</i> , 2018, 10, e2685.   | 0.2 | 2         |
| 642 | Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations. <i>Drugs in Context</i> , 2018, 7, 1-9.  | 1.0 | 3         |
| 644 | Time to go functional! Determining tumors' DNA repair capacity ex vivo. <i>Oncotarget</i> , 2018, 9, 36826-36827.  | 0.8 | 0         |
| 645 | Advances in the Treatment of Endometrial and Ovarian Cancer. <i>Oncology &amp; Hematology Review</i> , 2019, 15, 23.   | 0.2 | 0         |
| 646 | Maintenance Treatment for Recurrent Ovarian Carcinoma — Evidence Supporting the Efficacy and Safety of PARP Inhibitors. <i>European Oncology and Haematology</i> , 2019, 15, 29.   | 0.0 | 1         |
| 647 | Genetics and Epigenetics of Mesothelioma. , 2019, , 45-67.   |     | 0         |
| 649 | Molecular Testing in Ovarian Cancer: Recommendations and Treatment Considerations. , 2020, , 171-186.  |     | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 650 | Genetics and the Gynecologic Patient. <i>Ochsner Journal</i> , 2020, 20, 446-451.   | 0.5 | 3         |
| 653 | U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review. <i>Clinical Cancer Research</i> , 2022, 28, 1058-1071.  | 3.2 | 11        |
| 654 | Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls. <i>Gynecologic Oncology</i> , 2021, 163, 217-219.  | 0.6 | 1         |
| 655 | Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data. <i>Advances in Therapy</i> , 2022, 39, 328-345.     | 1.3 | 9         |
| 656 | Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2020, 20, 853-867.  | 0.8 | 1         |
| 658 | Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. <i>Targeted Oncology</i> , 2021, 16, 59-68.  | 1.7 | 9         |
| 660 | Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine. <i>Genes and Diseases</i> , 2022, 9, 668-681.  | 1.5 | 12        |
| 661 | Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer. , 2020, 1, 26-52.  |     | 0         |
| 662 | Current and Future Directions for PARP Inhibition. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 297-300.   | 0.2 | 0         |
| 663 | Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 666815.   | 1.3 | 9         |
| 664 | Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score. <i>Clinical Cancer Research</i> , 2022, 28, 1412-1421. | 3.2 | 46        |
| 665 | Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review. <i>P and T</i> , 2018, 43, 549-556.   | 1.0 | 9         |
| 666 | CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 1140-1155.           | 1.4 | 9         |
| 668 | Treatment algorithm in patients with ovarian cancer. <i>Facts, Views &amp; Vision in ObGyn</i> , 2020, 12, 227-239.   | 0.5 | 2         |
| 669 | PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. <i>Advances in Genetics</i> , 2021, 108, 35-80.  | 0.8 | 5         |
| 670 | Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. <i>Cancer Letters</i> , 2022, 526, 41-52.   | 3.2 | 9         |
| 672 | Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations. <i>Frontiers in Pharmacology</i> , 2021, 12, 743073.   | 1.6 | 10        |
| 673 | BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. <i>Genes</i> , 2021, 12, 1917.  | 1.0 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 674 | Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. <i>British Journal of Cancer</i> , 2022, 126, 576-585.                       | 2.9 | 7         |
| 675 | Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 653-661. | 3.2 | 10        |
| 676 | Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study. <i>Annals of Translational Medicine</i> , 2021, 9, 1661-1661.  | 0.7 | 11        |
| 677 | Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline <i>BRCA1/2</i> mutation. <i>European Journal of Cancer</i> , 2021, 159, 283-295.   | 1.3 | 24        |
| 678 | Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer. <i>Reproductive Biology and Endocrinology</i> , 2021, 19, 178.  | 1.4 | 17        |
| 679 | Comparison of somatic mutation landscapes in Chinese versus European breast cancer patients. <i>Human Genetics and Genomics Advances</i> , 2021, 3, 100076.   | 1.0 | 3         |
| 680 | European experts consensus: <i>BRCA</i> /homologous recombination deficiency testing in first-line ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, 276-287.   | 0.6 | 68        |
| 682 | Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells. <i>Cell Cycle</i> , 2022, 21, 379-391.  | 1.3 | 8         |
| 683 | Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer. <i>Neoplasia</i> , 2022, 24, 63-75.  | 2.3 | 14        |
| 684 | Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 432-440.   | 1.0 | 5         |
| 685 | The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 491-500.  | 1.0 | 4         |
| 686 | Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <i>BRCA1/2</i> -Mutated Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1383-1390.  | 3.2 | 12        |
| 687 | Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. <i>BMC Cancer</i> , 2022, 22, 13.  | 1.1 | 15        |
| 688 | Examining the prevalence of homologous recombination repair defects in ER+ breast cancers. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 649.  | 1.1 | 2         |
| 689 | Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 328-332.  | 0.5 | 4         |
| 690 | <i>NTRK</i> gene fusions are detected in both secretory and nonsecretory breast cancers. <i>Pathology International</i> , 2022, 72, 187-192.  | 0.6 | 9         |
| 691 | Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups. <i>Gynecologic Oncology</i> , 2022, 164, 558-565.  | 0.6 | 9         |
| 692 | <i>PARP</i> mediated <i>DNA</i> damage response, genomic stability and immune responses. <i>International Journal of Cancer</i> , 2022, 150, 1745-1759.   | 2.3 | 18        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 693 | The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 60.                             | 2.4 | 35        |
| 694 | Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy. <i>Npj Precision Oncology</i> , 2022, 6, 7.   | 2.3 | 11        |
| 695 | Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. <i>Gynecologic Oncology</i> , 2022, 164, 245-253. | 0.6 | 15        |
| 696 | Therapeutic Targeting of DNA Damage Response in Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1701.  | 1.8 | 26        |
| 697 | Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment. <i>European Journal of Cancer</i> , 2022, 163, 44-54.   | 1.3 | 14        |
| 698 | Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers. <i>Gynecologic Oncology</i> , 2022, 165, 49-52.  | 0.6 | 15        |
| 699 | Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 836984.                         | 2.0 | 22        |
| 700 | Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review. <i>Future Oncology</i> , 2022, 18, 1627-1650.  | 1.1 | 3         |
| 701 | The role of PARP inhibitors in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103621.  | 2.0 | 7         |
| 702 | Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103539.                                     | 2.0 | 11        |
| 703 | The Use of Targeted Agents in the Treatment of Gynecologic Cancers. <i>Current Treatment Options in Oncology</i> , 2022, 23, 15-28.   | 1.3 | 3         |
| 704 | Neurological complications of gynecological cancers. , 2022, , 353-364.   |     | 0         |
| 705 | Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations. <i>Cancers</i> , 2022, 14, 1132.  | 1.7 | 8         |
| 706 | PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 165-180.  | 1.0 | 15        |
| 707 | RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 185-199.                       | 1.5 | 16        |
| 708 | Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. <i>Cancers</i> , 2022, 14, 1253.  | 1.7 | 69        |
| 709 | PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 1003.  | 1.7 | 18        |
| 710 | Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. <i>Cancers</i> , 2022, 14, 953.  | 1.7 | 16        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 711 | Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. The Cochrane Library, 2022, 2022, CD007929.  | 1.5 | 22        |
| 712 | Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Cancer Management and Research, 2022, Volume 14, 673-686.                                       | 0.9 | 4         |
| 713 | Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy. Current Cancer Drug Targets, 2022, 22, 530-536.   | 0.8 | 4         |
| 714 | Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. Cancers, 2022, 14, 897.  | 1.7 | 13        |
| 715 | Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives. Cancers, 2022, 14, 1098.   | 1.7 | 8         |
| 716 | Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study. Anticancer Research, 2022, 42, 2017-2022.                         | 0.5 | 8         |
| 717 | Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers. Current Oncology Reports, 2022, 24, 889-904.  | 1.8 | 3         |
| 718 | Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing. Cancers, 2022, 14, 1434.                                  | 1.7 | 6         |
| 719 | Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. Cancers, 2022, 14, 1388.  | 1.7 | 22        |
| 720 | Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted Therapy. Diagnostics, 2022, 12, 842.  | 1.3 | 15        |
| 721 | Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma. Cell Communication and Signaling, 2022, 20, 39.   | 2.7 | 0         |
| 722 | Practice guidelines for <i>BRCA1/2</i> tumour testing in ovarian cancer. Journal of Medical Genetics, 2022, 59, 727-736.  | 1.5 | 4         |
| 723 | Templated Insertions Are Associated Specifically with <i>BRCA2</i> Deficiency and Overall Survival in Advanced Ovarian Cancer. Molecular Cancer Research, 2022, 20, 1061-1070.  | 1.5 | 1         |
| 724 | Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.   | 0.8 | 96        |
| 725 | A phase I study of talazoparib ( <i>BMN</i> 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors ( <i>NCI9782</i> ). Cancer Medicine, 2022, 11, 3969-3981.  | 1.3 | 11        |
| 726 | Rucaparib for <i>BRCA1/2</i> -mutated pretreated ovarian cancer: reflections from the ARIEL4 trial. Lancet Oncology, The, 2022, 23, 440-441.  | 5.1 | 1         |
| 727 | Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious <i>BRCA1</i> or <i>BRCA2</i> mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 465-478. | 5.1 | 70        |
| 728 | Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. European Journal of Cancer, 2022, 166, 87-99.   | 1.3 | 21        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 729 | Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. JCI Insight, 2021, 6, .  | 2.3 | 15        |
| 730 | PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers, 2021, 13, 6385.   | 1.7 | 19        |
| 731 | The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. Journal of Hematology and Oncology, 2021, 14, 206.                         | 6.9 | 24        |
| 732 | Targeting DNA repair pathway in cancer: Mechanisms and clinical application. MedComm, 2021, 2, 654-691.   | 3.1 | 34        |
| 733 | Organoids and epithelial ovarian cancer – a future tool for personalized treatment decisions?. Molecular and Clinical Oncology, 2021, 16, 29.   | 0.4 | 2         |
| 734 | Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer. Pharmaceuticals, 2021, 14, 1270.   | 1.7 | 5         |
| 735 | Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency. Scientific Reports, 2021, 11, 24022.   | 1.6 | 5         |
| 736 | Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma. Frontiers in Oncology, 2021, 11, 603591.  | 1.3 | 3         |
| 737 | Artificial intelligence, molecular subtyping, biomarkers, and precision oncology. Emerging Topics in Life Sciences, 2021, 5, 747-756.   | 1.1 | 1         |
| 738 | Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.   | 0.4 | 40        |
| 739 | Appropriate Selection of PARP Inhibitors in Ovarian Cancer. Current Treatment Options in Oncology, 2022, 23, 887-903.   | 1.3 | 17        |
| 740 | PARP inhibitors as single agents and in combination therapy; the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opinion on Investigational Drugs, 2022, 31, 607-631. | 1.9 | 20        |
| 741 | Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors. Cancer Chemotherapy and Pharmacology, 2022, 89, 671-682.   | 1.1 | 7         |
| 742 | An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 683-695.  | 1.1 | 6         |
| 745 | Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas. Npj Precision Oncology, 2022, 6, 29.  | 2.3 | 6         |
| 746 | Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. Expert Review of Proteomics, 2022, 19, 115-129.  | 1.3 | 3         |
| 747 | Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer. Journal of Central South University (Medical Sciences), 2021, 46, 644-652.   | 0.1 | 0         |
| 748 | Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors. Frontiers in Oncology, 2022, 12, 753311.  | 1.3 | 1         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 752 | Development of 1-(4-(Substituted)piperazin-1-yl)-2-((2-((4-methoxybenzyl)thio)pyrimidin-4-yl)oxy)ethanones That Target Poly (ADP-Ribose) Polymerase in Human Breast Cancer Cells. <i>Molecules</i> , 2022, 27, 2848.                     | 1.7 | 5         |
| 753 | Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1115-1124.                                    | 1.9 | 3         |
| 754 | The Landscape of Personalized Medicine in Gynecologic Cancer. <i>Advances in Oncology</i> , 2022, 2, 99-105.   | 0.1 | 1         |
| 755 | Investigation of BRCA1 methylation and FAT3 mutation as a potential biomarker in ovarian cancer samples. , 2022, 33, 201032.   |     | 1         |
| 757 | The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103725.  | 2.0 | 1         |
| 758 | Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance. <i>Cancers</i> , 2022, 14, 2504.   | 1.7 | 12        |
| 759 | STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. <i>Nature Communications</i> , 2022, 13, .   | 5.8 | 68        |
| 760 | Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?. <i>Cancers</i> , 2022, 14, 2561.  | 1.7 | 4         |
| 761 | Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 28.  | 1.3 | 4         |
| 762 | Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. <i>Gynecologic Oncology</i> , 2022, 166, 351-357.  | 0.6 | 8         |
| 763 | Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions. <i>Surgical Pathology Clinics</i> , 2022, , .  | 0.7 | 0         |
| 764 | Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review. <i>Kreativna Hirurgija I Onkologija</i> , 2022, 12, 48-55.   | 0.1 | 0         |
| 766 | A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2022, 5, 662-6.                              | 0.9 | 1         |
| 767 | Ovarian cancer recurrence: â€œis the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?â€• <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2022, 5, 451-458.                             | 0.9 | 6         |
| 768 | A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENAâ€“MONO/GOG-3020/ENGOT-ov45). <i>Journal of Clinical Oncology</i> , 2022, 40, 3952-3964. | 0.8 | 125       |
| 769 | A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. <i>Current Oncology</i> , 2022, 29, 4354-4369.              | 0.9 | 1         |
| 770 | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .   | 5.8 | 51        |
| 771 | The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. <i>Cancers</i> , 2022, 14, 2950.  | 1.7 | 9         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 772 | Breast cancer in the era of precision medicine. <i>Molecular Biology Reports</i> , 2022, 49, 10023-10037.  | 1.0 | 19        |
| 774 | Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. <i>European Journal of Cancer</i> , 2022, 171, 232-241.                                   | 1.3 | 7         |
| 775 | Molecular Mechanisms of Parthanatos and Its Role in Diverse Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7292.   | 1.8 | 31        |
| 776 | Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. <i>Facts, Views &amp; Vision in ObGyn</i> , 2022, 14, 111-120.   | 0.5 | 1         |
| 777 | Clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on CD133 and HE4 expression in advanced epithelial ovarian cancer. <i>Pakistan Journal of Medical Sciences</i> , 2022, 38, .  | 0.3 | 0         |
| 778 | Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?. <i>South Asian Journal of Cancer</i> , 0, , .   | 0.2 | 0         |
| 779 | Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis. <i>Gynecologic Oncology</i> , 2022, 166, 425-431.                                    | 0.6 | 12        |
| 780 | Reconsidering the mechanisms of action of <sc>PARP</sc> inhibitors based on clinical outcomes. <i>Cancer Science</i> , 2022, 113, 2943-2951.   | 1.7 | 11        |
| 781 | Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8577.  | 1.2 | 49        |
| 782 | Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. <i>JCO Precision Oncology</i> , 2022, , .  | 1.5 | 10        |
| 783 | Niraparib treatment for patients with <i>BRCA</i>-mutated ovarian cancer: review of clinical data and therapeutic context. <i>Future Oncology</i> , 2022, 18, 2505-2536.   | 1.1 | 4         |
| 784 | Identification of Ubiquitin-Related Gene-Pair Signatures for Predicting Tumor Microenvironment Infiltration and Drug Sensitivity of Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 3478.  | 1.7 | 1         |
| 785 | The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8125.  | 1.8 | 9         |
| 786 | Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1164-1170.   | 1.2 | 12        |
| 787 | Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy. <i>Molecules</i> , 2022, 27, 4736.  | 1.7 | 10        |
| 788 | Hematological toxicities in <sc>PARP</sc> inhibitors: A real-world study using <sc>FDA</sc> adverse event reporting system (<sc>FAERS</sc>) database. <i>Cancer Medicine</i> , 2023, 12, 3365-3375.  | 1.3 | 18        |
| 789 | Epithelial tumor compartment- and adjacent stromal compartment-specific expression of PARP1 in different anatomical sites in patients with HGSOC. <i>Genome Instability &amp; Disease</i> , 2022, 3, 201-208.  | 0.5 | 0         |
| 791 | A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 54-64. | 0.8 | 17        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 792 | Life after SOLO-2: Is Olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi) resistant, recurrent ovarian cancer?. <i>Annals of Oncology</i> , 2022, , .                                | 0.6 | 5         |
| 793 | PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies. <i>Frontiers in Pharmacology</i> , 0, 13, .   | 1.6 | 10        |
| 794 | Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma. <i>Genes</i> , 2022, 13, 1398.                              | 1.0 | 1         |
| 795 | BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. <i>Cancers</i> , 2022, 14, 3888.   | 1.7 | 56        |
| 796 | Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial. <i>Clinical Cancer Research</i> , 2022, 28, 4186-4193. | 3.2 | 20        |
| 798 | Bioinformatics: From NGS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice. <i>Biomedicines</i> , 2022, 10, 2074.  | 1.4 | 10        |
| 799 | CDCA3 exhibits a role in promoting the progression of ovarian cancer. <i>Tissue and Cell</i> , 2022, 79, 101903.  | 1.0 | 3         |
| 800 | Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOE patients. <i>Pathology Research and Practice</i> , 2022, 238, 154074.  | 1.0 | 4         |
| 801 | The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9981.   | 1.8 | 2         |
| 802 | Homologous Recombination Deficiency Scar: Mutations and Beyondâ€”Implications for Precision Oncology. <i>Cancers</i> , 2022, 14, 4157.  | 1.7 | 5         |
| 803 | Identification of Shared Neoantigens in BRCA1-Related Breast Cancer. <i>Vaccines</i> , 2022, 10, 1597.  | 2.1 | 3         |
| 804 | Impact of BRCA Gene Testing on Ovarian Cancer Management. <i>European Journal of Medical and Health Sciences</i> , 2022, 4, 1-6.  | 0.1 | 0         |
| 805 | A clinical case of repeat use of PARP inhibitors in a patient with &lt;i>mBRCA&/i>-associated ovarian cancer. <i>Siberian Journal of Oncology</i> , 2022, 21, 156-164.  | 0.1 | 0         |
| 806 | Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1477-1493.  | 1.6 | 6         |
| 807 | HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data. <i>Frontiers in Genetics</i> , 0, 13, .   | 1.1 | 1         |
| 808 | Leveraging an Informatics Approach to Identify an Unmet Clinical Need for <i>BRCA1</i></i></i> Testing Among Patients With Ovarian Cancer. <i>JCO Clinical Cancer Informatics</i> , 2022, , .                                 | 1.0 | 0         |
| 809 | PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. , 0, , .   |     | 0         |
| 810 | Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 40-49.  | 3.2 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 811 | Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient hepatocellular carcinoma. <i>Hepatology</i> , 2023, 78, 452-467.   | 3.6 | 3         |
| 813 | Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers. <i>Cancers</i> , 2022, 14, 4724.   | 1.7 | 0         |
| 815 | Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. <i>Cancers</i> , 2022, 14, 4621.   | 1.7 | 3         |
| 816 | Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1105-1117.  | 1.0 | 7         |
| 817 | Treatment of Advanced-Stage Ovarian Cancer. , 2022, , 105-119.   |     | 0         |
| 818 | Personalized Treatment in Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 1-19.   | 0.0 | 0         |
| 819 | Integrated Molecular Analysis Reveals 2 Distinct Subtypes of Pure Seminoma of the Testis. <i>Cancer Informatics</i> , 2022, 21, 117693512211326.   | 0.9 | 8         |
| 820 | Clinical Relevance of BRCA1/2 Pathogenic Variants and Impaired DNA Repair Pathways in Ovarian Carcinomas. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 59-76.  | 0.0 | 0         |
| 822 | State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. <i>JCO Precision Oncology</i> , 2022, , .   | 1.5 | 2         |
| 824 | Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1649-1675.  | 1.6 | 23        |
| 825 | Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. <i>Biomedicines</i> , 2022, 10, 2511.   | 1.4 | 10        |
| 826 | Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .   | 3.1 | 25        |
| 827 | Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report. <i>Cureus</i> , 2022, , .  | 0.2 | 0         |
| 828 | DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2022, , . | 0.6 | 1         |
| 829 | Integrative Genomic Tests in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13129.  | 1.8 | 8         |
| 830 | Exploring the DNA damage response pathway for synthetic lethality. <i>Genome Instability &amp; Disease</i> , 2023, 4, 98-120.  | 0.5 | 2         |
| 832 | Molecular hallmarks of cancer. , 2023, , 489-505.e5.   |     | 0         |
| 833 | Epithelial ovarian cancer. , 2023, , 250-281.e8.   |     | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 834 | Targeted therapy and molecular genetics. , 2023, , 464-488.e11.  |     | 0         |
| 835 | Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse. Current Oncology Reports, 2022, 24, 1685-1693.   | 1.8 | 6         |
| 836 | BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy. Cancers, 2022, 14, 5619.  | 1.7 | 3         |
| 837 | Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma. Cells, 2022, 11, 3563.  | 1.8 | 1         |
| 838 | <scp>Pyrroleâ€based EGFR</scp> inhibitors for the treatment of <scp>NCSLC</scp>: Binding modes and <scp>SARs</scp> investigations. Chemical Biology and Drug Design, 2023, 101, 195-217.        | 1.5 | 2         |
| 839 | Avelumab Plus Talazoparib in Patients With <i>BRCA1/2</i>- or <i>ATM</i>-Altered Advanced Solid Tumors. JAMA Oncology, 2023, 9, 29.  | 3.4 | 21        |
| 840 | Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. Breast Cancer Research, 2022, 24, .                 | 2.2 | 4         |
| 841 | PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer. European Medical Journal Oncology, 0, , 68-76.  | 0.0 | 1         |
| 842 | The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture. European Medical Journal Oncology, 0, , 2-15.  | 0.0 | 0         |
| 843 | Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?. International Journal of Gynecological Cancer, 2023, 33, 607-618.  | 1.2 | 1         |
| 844 | [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study. Clinical Cancer Research, 2023, 29, 1515-1527. | 3.2 | 6         |
| 845 | DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. International Journal of Molecular Sciences, 2022, 23, 14672.  | 1.8 | 26        |
| 846 | Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. Biomedicines, 2022, 10, 3008.   | 1.4 | 0         |
| 847 | Concordance between single-nucleotide polymorphismâ€based genomic instability assays and a next-generation sequencingâ€based homologous recombination deficiency test. BMC Cancer, 2022, 22, . | 1.1 | 4         |
| 848 | Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations. BMC Cancer, 2022, 22, .  | 1.1 | 2         |
| 849 | The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nature Genetics, 2022, 54, 1853-1864.   | 9.4 | 24        |
| 850 | Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report. Frontiers in Oncology, 0, 12, .                  | 1.3 | 1         |
| 851 | Towards Personalized Management of Ovarian Cancer. Cancer Management and Research, 0, Volume 14, 3469-3483.  | 0.9 | 4         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 852 | Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, 6, 31-49.  | 0.6  | 1         |
| 853 | Targeting DNA damage response pathways in cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 78-94.   | 12.8 | 158       |
| 854 | Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. <i>British Journal of Cancer</i> , 0, , .   | 2.9  | 2         |
| 855 | Shallow Whole-Genome Sequencing of Cell-Free DNA (cfDNA) Detects Epithelial Ovarian Cancer and Predicts Patient Prognosis. <i>Cancers</i> , 2023, 15, 530.  | 1.7  | 0         |
| 856 | Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. <i>Journal of Ovarian Research</i> , 2023, 16, .  | 1.3  | 8         |
| 857 | DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities. <i>Cancers</i> , 2023, 15, 448.  | 1.7  | 7         |
| 858 | Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. <i>Annals of Pharmacotherapy</i> , 0, , 106002802211491.                    | 0.9  | 0         |
| 860 | Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?. <i>South Asian Journal of Cancer</i> , 2022, 11, 207-212.  | 0.2  | 0         |
| 861 | Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer. <i>Npj Precision Oncology</i> , 2022, 6, .   | 2.3  | 8         |
| 862 | Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601. <i>Anti-Cancer Drugs</i> , 2023, 34, 857-865.                           | 0.7  | 2         |
| 863 | Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2023, Publish Ahead of Print, .  | 1.0  | 1         |
| 864 | Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. <i>JCO Precision Oncology</i> , 2023, , .                                       | 1.5  | 13        |
| 865 | Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy. <i>International Journal of Clinical Oncology</i> , 0, , . | 1.0  | 0         |
| 866 | The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. <i>Gynecologic Oncology</i> , 2023, 170, 172-178. | 0.6  | 0         |
| 867 | Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention. <i>Biomolecules</i> , 2023, 13, 653.  | 1.8  | 0         |
| 868 | The Role of PARP Inhibitors in the Treatment of Advanced Epithelial Ovarian Carcinoma. , 2022, , .  |      | 0         |
| 869 | Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. <i>Biology</i> , 2023, 12, 218.  | 1.3  | 27        |
| 870 | Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 207-216.   | 1.1  | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 871 | Pyrosequencing Assay for BRCA1 Methylation Analysis. <i>Journal of Molecular Diagnostics</i> , 2023, 25, 217-226.  | 1.2 | 1         |
| 872 | The PARP inhibitor Rucaparib synergizes with radiation to attenuate atypical teratoid rhabdoid tumor growth. <i>Neuro-Oncology Advances</i> , 2023, 5, .   | 0.4 | 1         |
| 873 | Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. <i>Genomics, Proteomics and Bioinformatics</i> , 2023, , .  | 3.0 | 2         |
| 874 | Small-Molecule-Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 599-615.  | 1.9 | 9         |
| 875 | Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10. <i>EBioMedicine</i> , 2023, 89, 104477. | 2.7 | 2         |
| 876 | Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 333-342.  | 1.9 | 2         |
| 877 | New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4044.  | 1.8 | 0         |
| 878 | Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. <i>Cancers</i> , 2023, 15, 1299.  | 1.7 | 5         |
| 879 | Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies. <i>Molecular Therapy - Oncolytics</i> , 2023, 28, 293-306.                         | 2.0 | 2         |
| 880 | Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311576.  | 1.4 | 3         |
| 881 | Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancer. <i>Experimental and Molecular Pathology</i> , 2023, 130, 104856.   | 0.9 | 0         |
| 882 | Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. <i>Oncologist</i> , 2023, 28, 319-326.   | 1.9 | 1         |
| 883 | Personalized Systemic Therapies in Hereditary Cancer Syndromes. <i>Genes</i> , 2023, 14, 684.  | 1.0 | 4         |
| 884 | Genomic testing in high-grade serous ovarian cancer: current options and future development. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 358-363.   | 1.2 | 0         |
| 885 | Overcoming PARP inhibitor resistance in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 364-376.  | 1.2 | 4         |
| 886 | Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer. <i>Medicine (United States)</i> , 2023, 102, e33271.   | 0.4 | 0         |
| 887 | Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel. <i>Journal of Molecular Diagnostics</i> , 2023, 25, 295-310.                                     | 1.2 | 1         |
| 888 | Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .   | 1.6 | 4         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 889 | Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. <i>Journal of Ovarian Research</i> , 2023, 16, . | 1.3 | 2         |
| 890 | Clinical Targeted Next-Generation Panel Sequencing Reveals <i>MYC</i> Amplification Is a Poor Prognostic Factor in Osteosarcoma. <i>JCO Precision Oncology</i> , 2023, , .                                 | 1.5 | 2         |
| 892 | Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit. <i>ESMO Open</i> , 2023, 8, 101209.    | 2.0 | 1         |
| 893 | PARP Inhibitors in Breast and Ovarian Cancer. <i>Cancers</i> , 2023, 15, 2357.   | 1.7 | 9         |
| 894 | Targeted therapy. , 2023, , 205-411.   |     | 0         |
| 895 | RAD50 Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors. <i>Current Cancer Drug Targets</i> , 2023, 23, .   | 0.8 | 0         |
| 906 | The power of whole genomic sequencing in biomedical research and clinical applications. , 2024, , 1-18.  |     | 0         |
| 929 | Recurrent Ovarian Cancer. , 2023, , 53-63.   |     | 0         |
| 935 | Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer. <i>Cancer Treatment and Research</i> , 2023, , 71-89.   | 0.2 | 0         |
| 937 | Development of Homologous Recombination Functional Assays for Targeting the DDR. <i>Cancer Treatment and Research</i> , 2023, , 43-70.   | 0.2 | 0         |
| 944 | ROS, Redox Regulation, and Anticancer Therapy. , 2023, , 311-409.  |     | 0         |
| 947 | Mutual Feedback Between Gynecological HBOC Practice and Cancer Genomic Medicine. , 2023, , 47-56.  |     | 0         |
| 959 | Homologous repair deficiency and PARP inhibitors in cancer management. , 2024, , 257-274.  |     | 0         |